Palantir Teams up with Fannie Mae
Quasi-governmental financial firm Fannie Mae on Wednesday announced a partnership with defense tech player Palantir (NASDAQ:PLTR) to detect mortgage fraud, deepening ties between the federal government and a company that has been a big winner in the second Trump administration.Priscilla Almodovar, Fannie Mae CEO, said Wednesday at a press event that the goal is for the firm to “identify fraud more proactively” with the help of Palantir, starting with its multi-family housing business. An early test showed that Palantir’s technology, which includes elements of artificial intelligence, could identify fraud in seconds that took human investigators two months to find, she said.Shares of Palantir have jumped more than 140% since President Donald Trump’s election win in November. The technology stock has roles in both modernizing the U.S. military and helping to cut costs in government, making it a seemingly strong fit for the administration’s stated priorities. CEO Alex Karp said Wednesday that the mortgage fraud detection can be done in a way that “protects the underlying data and protects the privacy of the people submitting their forms.”The announcement comes as there is a push to potentially bring Fannie and Freddie out of conservatorship and re-establish them as something closer to independent companies.PLTR shares dipped 53 cents to $123.23.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


